Breaking News, Collaborations & Alliances

NeoTX, MedImmune Announce Clinical Collaboration

To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI

Active Biotech’s partner, NeoTX, has entered a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca’s IMFINZI.    IMFINZI (durvalumab) is a human monoclonal antibody that blocks the immune checkpoint protein programmed death-ligand (PD-L1). Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters